A rapid, simple, efficient and stable method based on LC-MS/MS for simultaneous determination of deuvortioxetine, vortioxetine and their carboxylic acid metabolite in rat plasma has been established and validated. Carbamazepine was utilized as the sole internal standard. Protein precipitation was used to extract the analytes and internal standard, which were separated on a Waters Xterra C18 chromatography column (2.1 mm × 150 mm, 5 μm). The mobile phases were methanol and a mixture of 0.1% formic acid and 10 mmol L−1 ammonium formate in water. Chromatographic separation was achieved by using an easy isocratic elution program with 70% of methanol and a flow rate of 0.2 mL min−1. The detection was performed in the multiple-reaction monitoring mode with positive electrospray ionization. The total running time was 5.5 min. Method validation demonstrated that the method was specific, precise, and accurate and showed good linear ranges of 5–1000 ng mL−1 for deuvortioxetine, 5–1000 ng mL−1 for vortioxetine and 25–5000 ng mL−1 for their metabolite, respectively. The precision and accuracy were acceptable, and the lower limit of quantification was identifiable and reproducible at 5 ng mL−1 for both deuvortioxetine and vortioxetine, and 25 ng mL−1 for their metabolite. The plasma samples were stable under different temperature and storage conditions. The method was successfully applied to a toxicokinetic study of deuvortioxetine in rats, which provided important information for further development and application of deuvortioxetine.
The aim of this work is to investigate the intestinal permeability of lamivudine and explore its absorption mechanism. Caco-2 cells monolayer and single-pass intestinal perfusion (SPIP) were selected for the investigation of lamivudine under different conditions, such as different concentration, absorption time, bidirectional transportation, and transportation with efflux transporters inhibitor. The concentration of lamivudine both in Caco-2 cells monolayer samples and SPIP samples was detected by HPLC-UV. Then the permeability parameters were calculated. The established HPLC-UV method reach the requirements for detection. There is no statistically difference between absorption parameters of lamivudine both in Caco-2 cells monolayer and SPIP (P > 0.05) under different dose groups. After transportation with efflux transporters inhibitor, the efflux rate of lamivudine in three dose groups was significantly decreased from 2.67, 2.59 and 2.59 to 1.78, 1.61, and 1.81 respectively. Lamivudine exhibits an absorption mechanism of passive diffusion. The absorption of lamivudine may be related to efflux transporters. In addition, lamivudine is a moderate-permeability drug in Biopharmaceutics Classification System.
Treatment of ocular infection involves pharmacotherapy with steroids and antibiotic drops, such as moxifloxacin hydrochloride (MFH) and dexamethasone sodium phosphate (DSP). To characterize the pharmacokinetics of these two compounds, we performed and validated a liquid chromatography-mass spectrometry (LC-MS/MS) method to quantify them in rabbit ocular tissues and plasma. We used protein precipitation to extract the compounds. The analyte and internal standard (IS) were separated using a Shim-pack Scepter C18 column. The mobile phase was composed of 0.1% formic acid water (A) and methanol (B). MFH and DSP were detected using positive ion electrostatic ionization (ESI) in multiple reaction monitoring mode (MRM). The calibration curves for both compounds showed good linearity over concentrations ranging from 0.5 to 200 ng/mL in rabbit ocular tissues and plasma. The lower limit of quantification for both MFH and DSP was 0.5 ng/mL. We validated this method for selectivity, linearity (r2 > 0.99), precision, accuracy, matrix effects, and stability. Thus, we used this method to assess the pharmacokinetic (PK) characteristics of MFH and DSP in rabbit ocular tissues and plasma after single doses. Our results indicate that this method can be used for the simultaneous analysis of moxifloxacin hydrochloride and dexamethasone sodium phosphate in clinical samples.
The potential effects of dimethylaminoethyl ginkgolid B on pregnant dams and embryo-fetal development had been investigated in both Sprague-Dawley rats and New Zealand white rabbits.